Johnson & Johnson agreed to acquire Intra-Cellular Therapies for $132 a share in cash for a total equity value of about $14.6 billion. The health-care company Monday said the deal adds to its portfolio lumateperone, an oral treatment for adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder.

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies

Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the market for brain disease treatments.

So $14.6 billion is the price tag that works out to about $132 per share and some information on intracellular. So this is a company that focuses on central nervous system disorders. Think mental health and neurological conditions.

Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system disorders, for about $14.6 billion.